{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:12:30Z","timestamp":1792793550293,"version":"4.5.0"},"reference-count":35,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b16-00825","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:18:47Z","timestamp":1488327527000},"page":"327-333","source":"Crossref","is-referenced-by-count":31,"title":["Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts"],"prefix":"10.1248","volume":"40","author":[{"given":"Takashi","family":"Kawakubo","sequence":"first","affiliation":[{"name":"Department of Genome-based Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Genome-based Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiro","family":"Shirotani","sequence":"additional","affiliation":[{"name":"Department of Genome-based Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"},{"name":"Unit for Dementia Research and Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Genome-based Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"},{"name":"Unit for Dementia Research and Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Genome-based Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"},{"name":"Unit for Dementia Research and Drug Discovery, Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Iwata N, Higuchi M, Saido TC. Metabolism of amyloid-\u03b2 peptide and Alzheimer\u2019s disease. Pharmacol. Ther.<\/i>, 108<\/b>, 129\u2013148 (2005).","DOI":"10.1016\/j.pharmthera.2005.03.010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the \u03b2-amyloid precursor protein in familial Alzheimer\u2019s disease increases \u03b2-protein production. Nature<\/i>, 360<\/b>, 672\u2013674 (1992).","DOI":"10.1038\/360672a0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cai XD, Golde TE, Younkin SG. Release of excess amyloid \u03b2 protein from a mutant amyloid \u03b2 protein precursor. Science<\/i>, 259<\/b>, 514\u2013516 (1993).","DOI":"10.1126\/science.8424174"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer\u2019s disease in the APP gene at the N-terminus of \u03b2-amyloid. Nat. Genet.<\/i>, 1<\/b>, 345\u2013347 (1992).","DOI":"10.1038\/ng0892-345"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gardiner KJ. Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol. Sci.<\/i>, 31<\/b>, 66\u201373 (2010).","DOI":"10.1016\/j.tips.2009.10.010"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Malt EA, Dahl RC, Haugsand TM, Ulvestad IH, Emilsen NM, Hansen B, Cardenas YE, Sk\u00f8ld RO, Thorsen AT, Davidsen EM. Health and disease in adults with Down syndrome. Tidsskr. Nor. Laegeforen.<\/i>, 133<\/b>, 290\u2013294 (2013).","DOI":"10.4045\/tidsskr.12.0390"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Al-Biltagi MA. Echocardiography in children with Down syndrome. World J. Clin. Pediatr.<\/i>, 2<\/b>, 36\u201345 (2013).","DOI":"10.5409\/wjcp.v2.i4.36"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. Lancet<\/i>, 355<\/b>, 165\u2013169 (2000).","DOI":"10.1016\/S0140-6736(99)05264-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Head E, Silverman W, Patterson D, Lott IT. Aging and Down syndrome. Curr. Gerontol. Geriatr. Res.<\/i>, 2012<\/b>, 412536 (2012).","DOI":"10.1155\/2012\/412536"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sago H, Carlson EJ, Smith DJ, Kilbridge J, Rubin EM, Mobley WC, Epstein CJ, Huang TT. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 95<\/b>, 6256\u20136261 (1998).","DOI":"10.1073\/pnas.95.11.6256"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tejedor FJ, H\u00e4mmerle B. MNB\/DYRK1A as a multiple regulator of neuronal development. FEBS J.<\/i>, 278<\/b>, 223\u2013235 (2011).","DOI":"10.1111\/j.1742-4658.2010.07954.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, Proud CG. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2B\u03b5 at Ser539<\/sup> and the microtubule-associated protein tau at Thr212<\/sup>: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J.<\/i>, 355<\/b>, 609\u2013615 (2001).","DOI":"10.1042\/bj3550609"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I, Dunckley T. \u03b2-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer\u2019s disease-related sites. PLoS ONE<\/i>, 6<\/b>, e19264 (2011).","DOI":"10.1371\/journal.pone.0019264"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS, Kim MJ, Son MY, Seo H, Chung SH, Song WJ. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer\u2019s disease. J. Neurochem.<\/i>, 104<\/b>, 1333\u20131344 (2008).","DOI":"10.1111\/j.1471-4159.2007.05075.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Adorno M, Sikandar S, Mitra SS, Kuo A, Nicolis Di Robilant B, Haro-Acosta V, Ouadah Y, Quarta M, Rodriguez J, Qian D, Reddy VM, Cheshier S, Garner CC, Clarke MF. Usp16 contributes to somatic stem-cell defects in Down\u2019s syndrome. Nature<\/i>, 501<\/b>, 380\u2013384 (2013).","DOI":"10.1038\/nature12530"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wang P, Alvarez-Perez JC, Felsenfeld DP, Liu H, Sivendran S, Bender A, Kumar A, Sanchez R, Scott DK, Garcia-Oca\u00f1a A, Stewart AF. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat. Med.<\/i>, 21<\/b>, 383\u2013388 (2015).","DOI":"10.1038\/nm.3820"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Asai M, Kinjo A, Kimura S, Mori R, Kawakubo T, Shirotani K, Yagishita S, Maruyama K, Iwata N. Perturbed calcineurin-NFAT signaling is associated with the development of Alzheimer\u2019s disease. Biol. Pharm. Bull.<\/i>, 39<\/b>, 1646\u20131652 (2016).","DOI":"10.1248\/bpb.b16-00350"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu S, Saido TC. Global brain delivery of NEP gene by intravascular administration of AAV vector in mice. Sci. Rep.<\/i>, 3<\/b>, 1472 (2013).","DOI":"10.1038\/srep01472"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Park J, Song WJ, Chung KC. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell. Mol. Life Sci.<\/i>, 66<\/b>, 3235\u20133240 (2009).","DOI":"10.1007\/s00018-009-0123-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sun X, Wu Y, Herculano B, Song W. RCAN1 overexpression exacerbates calcium overloading-induced neuronal apoptosis. PLoS ONE<\/i>, 9<\/b>, e95471 (2014).","DOI":"10.1371\/journal.pone.0095471"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Wong H, Levenga J, Cain P, Rothermel B, Klann E, Hoeffer C. RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer\u2019s disease. Acta Neuropathol.<\/i>, 130<\/b>, 829\u2013843 (2015).","DOI":"10.1007\/s00401-015-1499-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. Activities of extract and constituents of Banisteriopsis caapi<\/i> relevant to parkinsonism. Pharmacol. Biochem. Behav.<\/i>, 75<\/b>, 627\u2013633 (2003).","DOI":"10.1016\/S0091-3057(03)00129-1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) G\u00f6ckler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J.<\/i>, 276<\/b>, 6324\u20136337 (2009).","DOI":"10.1111\/j.1742-4658.2009.07346.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Cheon MS, Dierssen M, Kim SH, Lubec G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids<\/i>, 35<\/b>, 339\u2013343 (2008).","DOI":"10.1007\/s00726-007-0618-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, Tabara Y, Miki T, Akatsu H, Kosaka K, Funakoshi E, Nishitomi K, Sakaguchi G, Kato A, Hattori H, Uema T, Takeda M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between \u03b2-amyloid production and tau phosphorylation in Alzheimer\u2019s disease. Hum. Mol. Genet.<\/i>, 16<\/b>, 15\u201323 (2007).","DOI":"10.1093\/hmg\/ddl437"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Bagyinszky E, Youn YC, An SS, Kim S. The genetics of Alzheimer\u2019s disease. Clin. Interv. Aging<\/i>, 9<\/b>, 535\u2013551 (2014).","DOI":"10.2147\/CIA.S51571"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ. A human stem cell model of early Alzheimer\u2019s disease pathology in Down syndrome. Sci. Transl. Med.<\/i>, 4<\/b>, 124ra29 (2012).","DOI":"10.1126\/scitranslmed.3003771"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat. Rev. Cancer<\/i>, 9<\/b>, 810\u2013820 (2009).","DOI":"10.1038\/nrc2735"},{"key":"29","unstructured":"29) Di Domenico F, Pupo G, Mancuso C, Barone E, Paolini F, Arena A, Blarzino C, Schmitt FA, Head E, Butterfield DA, Perluigi M. Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1\/BVR-a system: insights for transition to Alzheimer\u2019s disease. J. Alzheimers Dis.<\/i>, 44<\/b>, 1107\u20131120 (2015)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Wolvetang EJ, Bradfield OM, Hatzistavrou T, Crack PJ, Busciglio J, Kola I, Hertzog PJ. Overexpression of the chromosome 21 transcription factor Ets2<\/i> induces neuronal apoptosis. Neurobiol. Dis.<\/i>, 14<\/b>, 349\u2013356 (2003).","DOI":"10.1016\/S0969-9961(03)00107-4"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chu J, Wisniewski T, Pratic\u00f2 D. GATA1-mediated transcriptional regulation of the \u03b3-secretase activating protein increases A\u03b2 formation in Down syndrome. Ann. Neurol.<\/i>, 79<\/b>, 138\u2013143 (2016).","DOI":"10.1002\/ana.24540"},{"key":"32","unstructured":"32) Vi\u00f1a J, Lloret A. Why women have more Alzheimer\u2019s disease than men: gender and mitochondrial toxicity of amyloid-\u03b2 peptide. J. Alzheimer\u2019s Dis.<\/i>, 20<\/b> (Suppl. 2), S527\u2013S533 (2010)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Liang K, Yang L, Yin C, Xiao Z, Zhang J, Liu Y, Huang J. Estrogen stimulates degradation of \u03b2-amyloid peptide by up-regulating neprilysin. J. Biol. Chem.<\/i>, 285<\/b>, 935\u2013942 (2010).","DOI":"10.1074\/jbc.M109.051664"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res.<\/i>, 1216<\/b>, 92\u2013103 (2008).","DOI":"10.1016\/j.brainres.2008.03.079"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Gardiner K. Transcriptional dysregulation in Down syndrome: predictions for altered protein complex stoichiometries and post-translational modifications, and consequences for learning\/behavior genes ELK, CREB, and the estrogen and glucocorticoid receptors. Behav. Genet.<\/i>, 36<\/b>, 439\u2013453 (2006).","DOI":"10.1007\/s10519-006-9051-1"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/3\/40_b16-00825\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T11:35:23Z","timestamp":1498390523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/3\/40_b16-00825\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00825","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}